$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Money / Business

Lundbeck Raised Its 2026 Guidance in November. Vyepti, Up 45 Percent, Is Why.

Nine-month revenue was DKK 20,191 million, up 13 percent at constant exchange rates. Strategic brands supplied DKK 15,951 million of it, 79 percent of the total, and full-year revenue growth guidance rose to 11 to 12 percent, with adjusted EBITDA growth guidance at 15 to 19 percent.

TML Markets DeskNov 11, 11:37 PM ET · 1 min read

Edited and fact-checked by Stephen Sprague

The entrance to Lundbeck’s headquarters in Valby, Copenhagen; the drugmaker raised its guidance on nine-month results. Photo: Johan Wessman / News Øresund / CC BY 2.0, via Wikimedia Commons.
Summary

Lundbeck raised its 2026 revenue growth guidance to 11 to 12 percent on nine-month revenue of DKK 20,191 million, up 13 percent at constant exchange rates.

Tap a passage. React to the part that matters.

Lundbeck raised its 2026 guidance on November 10 after nine-month revenue grew 13 percent at constant exchange rates. The release names the driver in its own headline: Vyepti.

The nine-month total is DKK 20,191 million, up 13 percent at constant exchange rates and 9 percent in kroner. On that base, Lundbeck raised full-year revenue growth guidance to 11 to 12 percent, from 7 to 9 percent.

The total breaks by brand. Strategic brands rose 16 percent at constant exchange rates to DKK 15,951 million, 79 percent of revenue: Vyepti at DKK 4,533 million, up 45 percent; Rexulti at DKK 5,071 million, up 13 percent; Brintellix/Trintellix at DKK 3,389 million, flat; and the Abilify long-acting injectable franchise at DKK 2,958 million, up 6 percent. By region, the United States supplied DKK 11,217 million, Europe DKK 4,714 million and International Operations DKK 4,000 million. EBITDA reached DKK 6,854 million, up 17 percent at constant exchange rates, and adjusted EBITDA DKK 7,026 million, up 19 percent. Earnings per share were DKK 4.11, up 30 percent in kroner, with adjusted EPS of DKK 5.42, up 25 percent. Third-quarter revenue alone was DKK 6,603 million, up 7 percent at constant exchange rates. Alongside the revenue raise, adjusted EBITDA growth guidance moved to 15 to 19 percent, from 8 to 14 percent.

Timing gives the raise its weight. A company lifting the bottom of its full-year revenue band by four points in the second week of November has most of the fourth quarter's orders in view. The concentration is stated in the same numbers: one portfolio, strategic brands, now produces nearly four-fifths of revenue, and one product in it, Vyepti, grew 45 percent. On the nine months reported, that concentration is the growth.

Four office chairs in a rowFor businessesAmazon Business is Amazon’s purchasing store for companies, with business accounts and quantity ordering.Register with Amazon Business

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.